Validation of a Risk Scoring System to Predict Life Expectancy after CEA in Patient with Asymptomatic Carotid Artery Stenosis  by Barbetta, I. et al.
396 European Journal of Vascular and Endovascular Surgery Volume 50 Issue 3 p. 390e404 September/2015operatively with suturing of the graft proximally due to poor proximal
seal without endoleaks.
Conclusion: Acute bEVAR of ruptured TAAA provides good results in the
short-term suggesting it as a valid option in the acute setting.
Analysis of 100 Reported Deaths after Elective TEVAR/EVAR in 1
Year Reveals At Least Half were Preventable!
R. Gambhir, H. Slim, H. Mistry, A. Choong, D. Valenti, H. Rashid
King’s College Hospital, London, United Kingdom
Introduction:
Objective: To analyse the cause of deaths following elective TEVAR and
EVAR as reported on manufactures and user facility device experience
(MAUDE) database of US FDA and identify areas of concern.
Methods: The MUADE database was searched for deaths associated
with the use of Aortic stent grafts. The search criteria used was ‘System,
Endovascular Graft, and Aortic Aneurysm’. Search was done retrospectively
from 31 Jan 2015 for 100 consecutive death reports.
Results: Six different Aortic stent graft systems had been used. There
was no report of device related death, all were procedure related with non
IFU use in over 20% of cases. 30% deaths occurred in peri-operative period
from causes like hypovolemia from aortic or iliac rupture, retrograde or
antegrade dissections, air embolism. Difﬁculty in deployment of stents or
accessories was reported in 15% and acute renal failure causing death in
25%. Open conversion was associated with death in over 90% of patients.
Delayed rupture with or without sac expansion was noted in 20% of pa-
tients. No cause of death was identiﬁed in 10% of patients.
Conclusion:Deaths after elective TEVAR/EVAR are a reality that cannot be
ignored. There is a need to take ownership of the reporting systems by
physicians. Better sharing of adverse events may help prevent some of these
deaths.
Intra-operative Analysis of Motor Evoked Potentials to Evaluate
the Risk of Paraplegia during Branched EVAR for Thoraco-
abdominal Aneurysm
P.M. Kasprzak, M. Wagenschwanz, B. Cucuruz, W. Mess, R. Kopp
Department of Vascular and Endovascular Surgery, University Hospital
Regensburg, Germany
Introduction: Spinal cord ischemia (SCI) is a major complication after aortic
repair of thoraco-abdominal aneurysms (TAAA). Recently, we introduced
the concept of temporary aneurysm sack perfusion (TASP) to prevent
paraplegia during branched EVAR for TAAA. These patients seem to have a
reduced risk for post-operative SCI, but they need a second procedure for
branch occlusion. Intra-operative assessment of the neurologic status using
motor evoked potentials (MEPs) might allow an intra-operative decision for
TASP and early or late side branch completion.
Methods: From 07/2007e01/2015, 105 patients with TAAA were
treated with branched standard or custom made endovascular stent grafts.
All patients received peri-operative spinal drainage. Temporary aneurysm
sack perfusion (TASP) was performed for SCI prevention in n ¼ 52 patients.
Intra-operative assessment of spinal cord function using MEPs was per-
formed in n ¼ 27 (26%) patients. In n ¼ 20 (19%) patients additional intra-
operative balloon occlusion of the TASP branch was performed. De-
mographic data, comorbidities, neurologic symptoms and variables related
to aneurysm or endovascular treatment were analyzed. Post-operative SCI
was deﬁned as motor deﬁciency (Tarlov 0e2) day 0e7 post-operatively and
day 30.
Results: Post-operative transitory neurologic deﬁciency was
observed in 21/105 (20%) patients and 13/105 (12%) patients had
paraplegia after 30 days. In the TASP group 3/52 (5.7 %) patients had
severe SCI after bEVAR, two of them after secondary branch occlusion.
None of these 2 patients had intra-operative MEPs monitoring. Based
on intra-operative MEPs monitoring with an additional side branch
balloon occlusion test for 45 min 7/20 patients with low risk of spinal
cord ischemia had intra-operative immediate side branch occlusion and
no paraplegia. In 13/20 patients a decrease of motor evoked potentialswas observed and these patients had TASP with secondary side branch
occlusion.
Conclusion: Neurologic monitoring during bEVAR with MEPs is feasible
and with relevant information regarding the risk of paraplegia and the
therapeutic concept including TASP.
Deﬁnite Plaque Echolucency is Associated with a Higher Risk of
Ipsilateral Ischaemic Stroke during Early Follow up in the
Asymptomatic Carotid Surgery Trial-1 (ACST-1)
A. Huibers, G.J. de Borst, R. Bulbulia, A. Hallidayon behalf ofACST-1
Collaborative Group
Nufﬁeld Department of Surgical Sciences, University of Oxford, Oxford, United
Kingdom
Introduction: Several carotid plaque characteristics, including a thin ﬁbrous
cap, lipid necrotic core and intraplaque haemorrhage, have been suggested
as potential markers to select patients at high risk for future stroke. On
ultrasound, these “high risk” characteristics appear echolucent. The
Asymptomatic Carotid Surgery Trial-1 (ACST-1) is the largest randomised
controlled trial comparing carotid endarterectomy (CEA) with deferral of
CEA in patients with severe asymptomatic carotid artery stenosis. We
aimed to assess whether ultrasound characterized plaque echogenicity was
a predictor for ischaemic stroke in asymptomatic patients randomized to
deferred treatment in ACST-1.
Methods: 814 patients randomized to deferred surgery who had
baseline plaque assessment conﬁdentially classiﬁed as echolucent (>25%
soft plaque) or non-echolucent (<25% soft plaque) were studied. Kaplan-
Meier survival curves were used to calculate cumulative rates of ipsilateral
ischaemic stroke in both groups.
Results: Life table analysis showed a signiﬁcantly higher 5 year risk of
ipsilateral stroke in patients with deﬁnite echolucent plaques (8.0%; 95% CI:
6.4 - 9.6) when compared to patients with deﬁnitely non-echolucent plaques
(3.1%; 2.1 - 4.1) (p ¼ 0.009). After adjustments of other risk factors, plaque
echolucency was associated with a 2.5 times increased risk of ipsilateral
ischaemic stroke (HR 2.52, 95% CI: 1.20e5.25; p ¼ 0.014). The use of lipid
lowering therapy was low in both groups during the ﬁrst 5 years after
randomization but rose signiﬁcantly thereafter and during the later stages of
follow up, and was more commonly prescribed in patients with echolucent
plaques (p ¼ 0.001). The risk of ipsilateral ischaemic stroke at 10 years was
similar for both levels of echogenicity (p ¼ 0.421) as was the risk of any
stroke at 10 years (p ¼ 0.632).
Conclusion: Deﬁnite plaque echolucency (>25% soft plaque) might be a
predictor of ipsilateral stroke and is associated with a higher 5 year ipsi-
lateral stroke risk in these trial patients with asymptomatic carotid disease.
The similar stroke risk outcomes at 10 years for both groups could possibly
be explained by a higher use of lipid lowering therapy during later follow
up in patients with deﬁnite echolucent plaques.
Validation of a Risk Scoring System to Predict Life Expectancy
after CEA in Patient with Asymptomatic Carotid Artery Stenosis
I. Barbetta, D. Bissacco, M. Carmo, S. Bonardelli, S. Trimarchi,
V. Catanese, P.G. Settembrini
U.O. di Chirurgia Vascolare, Ospedale S.Carlo Borromeo, Università di Milano e
Cattedra di Chirurgia Vascolare, Spedali Civili di Brescia, Università di Brescia e
U.O. di Chirurgia Vascolare II, IRCCS Policlinico di S.Donato, Università di Milano,
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Introduction: Recent guidelines regarding surgical treatment of asymp-
tomatic carotid stenosis recommend exclusion of patients without a min-
imum life-expectancy of 3 e5 years. Purpose of this study is to validate a
previously derived risk scoring system to identify factors associated with a
higher mortality during long-term follow up after carotid endarterectomy
(CEA).
Methods: The factors were derived from a cohort of 648 asymptomatic
patients. According to the weight of each variable, the score system
included age (<70 ¼ 0 points, 70e79 ¼ 4 points, 80 ¼ 8 points), renal
status (creatinine 1.5 ¼ 4 points and dialysis ¼ 8 points), chronic
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disease (CAD), lack of statins on treatment (1 point each). We calculated
the total risk score as the sum of all risk factors’ points, and grouped them
into 4 categories. Another 334 asymptomatic patients were extracted from
two tertiary care medical centers to derive a validation cohort (VC). The
derivation cohort (DC) and VC were clinically similar in terms of age (74 vs.
72 years) and gender (males 66% vs. 63%). Among risk factors, they
differed only for CAD (20% vs. 30% P < 0.001) and statin therapy (44% vs.
60% P < 0.001). They were comparable as per diabetes (29% vs. 24%
P ¼ 0.09), mean creatinine (1.13 vs. 1.1 mg/dL, P ¼ 0.58) and COPD (13.2%
vs. 10.5%, 0.21).
Results: Median follow up was 56 months for DC and 65 months for VC.
Long term mortality was comparable among DC and VC: overall survival
was 98.9  0.4% vs. 96.7  0.1% at 1 year; 92.7  1.1% vs. 91  1.6% at 3
years and 84.7  1.7% vs. 85.2  2% at 5 years.When comparing groups, 5
years survival rate was 97  1.5% for patients with score 0e3, 88.4  2.2%
for score 4e7, 69.6  4.7% for score 8e11, and 48.1  13.5% for score
12 (P < 0.0001) in the DC (ﬁg. 1). Similarly in the VC we found a
95.5  2% 5 years survival for score 0e3, 89.5  2.7% for score 4e7,
65  6.1% for score 8e11 and 44.8  14.1% for score 12 (P < 0.0001).
Conclusion: Our scoring system is a simple, 6 variables clinical tool for
prediction of post-operative life expectancy. The score showed to predict
adequately the long-term survival in a validation cohort from two different
medical centers. Patients with a score >8 have a poor long term survival,
and the advantage of CEA in this subgroup is questionable.We believe that
our score may help clinicians while selecting asymptomatic patients who
would beneﬁt from CEA.
Stroke/Death Rates Following Carotid Artery Stenting and
Carotid Endarterectomy in Contemporary Administrative Dataset
Registries: A Systematic Review.
K.I. Paraskevas, E.L. Kalmykov, A.R. Naylor
Leicester Royal Inﬁrmary, Leicester, United Kingdom
Introduction: Randomized trials have reported contradictory ﬁndings
regarding outcomes after carotid artery stenting (CAS) versus carotid
endarterectomy (CEA). Despite this, the 2011 American Heart Association
(AHA) guidelines expanded CAS indications, partly because of data from the
Carotid Revascularization Endarterectomy versus Stenting Trial (CREST), but
also because of improving outcomes in Industry-sponsored ‘high risk for
CEA’ CAS Registries. The aim of the current systematic review was to see
whether there was a parallel reduction in procedural risk after CAS in
contemporary administrative dataset registries.
Methods: PubMed/Medline, Embase and Cochrane databases were
systematically searched from January 1, 2008 until February 23, 2015 for
administrative dataset registries reporting outcomes after both CEA and
CAS.
Results: Twenty-one registries reported outcomes after >1,500,000
procedures. CAS had similar stroke/death rates with CEA in one registry
involving ‘average risk’ asymptomatic and in two registries involving
‘average risk’ symptomatic patients. Stroke/death rates after CAS were
signiﬁcantly higher than CEA in 9/15 registries involving ‘average risk’
asymptomatic and in 11/18 registries involving ‘average risk’ symptomatic
patients. In ﬁve registries, CAS was associated with higher stroke/death
rates than CEA for both symptomatic and asymptomatic patients, but
formal statistical comparison was not reported. CAS was associated with
stroke/death rates that exceeded risk thresholds recommended by the AHA
in 9/15 registries involving ‘average risk’ asymptomatic patients and in 13/
18 registries involving ‘average risk’ symptomatic patients. In 5/18 regis-
tries, the procedural risk after CAS in ‘average risk’ symptomatic patients
exceeded 10%.
Conclusion: Data from contemporary administrative dataset registries
suggest that stroke/death rates following CAS remain signiﬁcantly higher
than after CEA and frequently exceed accepted AHA thresholds. In this
systematic review, there was no evidence of a sustained decline in pro-
cedural risk after CAS. The extremely high published risks in some
symptomatic registries suggest that clinical governance is not being ap-
plied.Genetic Polymorphisms Inﬂuence in the Response to Clopidogrel
in Peripheral Artery Disease Patients Following Percutaneous
Transluminal Angioplasty
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Introduction: Clopidogrel has provided signiﬁcant reduction in major
vascular events in patients with peripheral artery disease (PAD), particu-
larly among those following PTA. Clopidogrel antiplatelet effects differ
according to genotype ABCB1 and CYP2C19, establishing normal, inter-
mediate and poor metabolizers; and good or bad carriers. Intermediate and
poor metabolizers (CYP2C19 *1/*2,*2/*2) and bad transporters (ABCB1TT)
are responsible for the poor antiplatelet drug response. These poly-
morphisms have been associated with differences in clopidogrel response
in acute coronary syndrome patients but effects in peripheral artery dis-
ease are still understudied.
To determine the onset of ischemic vascular events requiring reopera-
tion of the affected limb or amputation in patients undergoing PTA (+/-
stent) during one year after treatment and to study the association with
the presence of genetic polymorphisms CYP2C19 and ABCB1 (separately
and combined) a case-control study was performed.
Methods: 72 patients with PAD of the lower limbs under PTA (+/- stent)
and treated with clopidogrel were selected. CYP2C19*2 (rs4244285),
CYP2C19*3 (rs4986893) and ABCB1 (rs1045642) polymorphisms were
genotyped using Taqman allelic discrimination technique to compare post-
operative results.
Results: Out of the 72 patients included in the study, 18 were
CYP2C19*2 allele carries, no patient carried CYP2C19*3 allele and 14 pa-
tients were ABCB1TT genotype. Out of the 72 patients, 25 (34.7%) had an
event during follow up (1 year). Patients with at least some loss of function
had a higher rate of events compared to patients with no loss of function
allele (OR ¼ 5.0, 95% CI 1.75 e14.27, p ¼ 0.003), and patients with some
loss of function allele were associated with a worse Fontaine evolution
(OR ¼ 13.96, 95% CI 4.44e43.82, p < 0.0001). Reduced and non metab-
olizer patients also had a higher rate of events compared to good
metabolizer patients (OR ¼ 4.49, 95% CI 1.25 e13.84, p ¼ 0.009) and a
worse outcome Fontaine grade (OR ¼ 8.31, 95% CI 2.36e29.16;
p ¼ 0.001). However, poor transporter patients didn’t show a statistically
signiﬁcant higher rate of events comparing to good transporters although
they showed a worse Fontaine grade evolution (OR ¼ 4.75, 95% CI 1.32e
17.07, p ¼ 0.017)
Conclusion: Poor metabolizer patients of clopidogrel have a higher
risk of major ischemic events and worst Fontaine grade evolution. Our
results support the role of CYP2C19 and ABCB1 polymorphisms as ge-
netic markers for vascular events in patients with peripheral vascular
disease of the lower limbs undergoing PTA and treated with clopidog-
rel.
Polymeric Microspheres as Novel Delivery Platform for Pro-
angiogenic Therapy
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P.H.A. Quax
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Introduction: Angiogenesis, the sprouting of new capillaries from the
microvasculature, improves blood perfusion of ischemic tissue. Various pro-
angiogenic factors have the potential to stimulate and enhance angio-
genesis. However, due to poor drug delivery and rapid clearance, clinical
trials on pro-angiogenic therapeutics in peripheral arterial disease have
only been marginally successful. We aimed to develop a polymer-based
drug delivery platform enabling local, sustained delivery of pro-angiogenic
